These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 32847033)
1. Clinical Trials for Use of Melatonin to Fight against COVID-19 Are Urgently Needed. Kleszczyński K; Slominski AT; Steinbrink K; Reiter RJ Nutrients; 2020 Aug; 12(9):. PubMed ID: 32847033 [TBL] [Abstract][Full Text] [Related]
2. COVID-19: Melatonin as a potential adjuvant treatment. Zhang R; Wang X; Ni L; Di X; Ma B; Niu S; Liu C; Reiter RJ Life Sci; 2020 Jun; 250():117583. PubMed ID: 32217117 [TBL] [Abstract][Full Text] [Related]
3. Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19. El-Missiry MA; El-Missiry ZMA; Othman AI Eur J Pharmacol; 2020 Sep; 882():173329. PubMed ID: 32615182 [TBL] [Abstract][Full Text] [Related]
4. COVID-19: Rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main Protease Inhibitor. Feitosa EL; Júnior FTDSS; Nery Neto JAO; Matos LFL; Moura MHS; Rosales TO; De Freitas GBL Int J Med Sci; 2020; 17(14):2133-2146. PubMed ID: 32922174 [TBL] [Abstract][Full Text] [Related]
5. Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19. Orienti I; Gentilomi GA; Farruggia G Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471278 [TBL] [Abstract][Full Text] [Related]
6. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. Lisi L; Lacal PM; Barbaccia ML; Graziani G Biochem Pharmacol; 2020 Oct; 180():114169. PubMed ID: 32710969 [TBL] [Abstract][Full Text] [Related]
7. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial. Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611 [TBL] [Abstract][Full Text] [Related]
8. In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm. Artigas L; Coma M; Matos-Filipe P; Aguirre-Plans J; Farrés J; Valls R; Fernandez-Fuentes N; de la Haba-Rodriguez J; Olvera A; Barbera J; Morales R; Oliva B; Mas JM PLoS One; 2020; 15(10):e0240149. PubMed ID: 33006999 [TBL] [Abstract][Full Text] [Related]
9. Lungs as target of COVID-19 infection: Protective common molecular mechanisms of vitamin D and melatonin as a new potential synergistic treatment. Martín Giménez VM; Inserra F; Tajer CD; Mariani J; Ferder L; Reiter RJ; Manucha W Life Sci; 2020 Aug; 254():117808. PubMed ID: 32422305 [TBL] [Abstract][Full Text] [Related]
10. Immune-Boosting, Antioxidant and Anti-inflammatory Food Supplements Targeting Pathogenesis of COVID-19. Mrityunjaya M; Pavithra V; Neelam R; Janhavi P; Halami PM; Ravindra PV Front Immunol; 2020; 11():570122. PubMed ID: 33117359 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy and safety of Melatonin in moderately ill patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Ziaei A; Davoodian P; Dadvand H; Safa O; Hassanipour S; Omidi M; Masjedi M; Mahmoudikia F; Rafiee B; Fathalipour M Trials; 2020 Oct; 21(1):882. PubMed ID: 33106171 [TBL] [Abstract][Full Text] [Related]
12. Melatonin, aging, and COVID-19: Could melatonin be beneficial for COVID-19 treatment in the elderly? Öztürk G; Akbulut KG; Güney Ş Turk J Med Sci; 2020 Oct; 50(6):1504-1512. PubMed ID: 32777902 [TBL] [Abstract][Full Text] [Related]
15. Repurposing existing drugs for COVID-19: an endocrinology perspective. Cadegiani FA BMC Endocr Disord; 2020 Sep; 20(1):149. PubMed ID: 32993622 [TBL] [Abstract][Full Text] [Related]
16. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Tufan A; Avanoğlu Güler A; Matucci-Cerinic M Turk J Med Sci; 2020 Apr; 50(SI-1):620-632. PubMed ID: 32299202 [TBL] [Abstract][Full Text] [Related]
17. Clinical trial to test the efficacy of melatonin in COVID-19. Acuña-Castroviejo D; Escames G; Figueira JC; de la Oliva P; Borobia AM; Acuña-Fernández C J Pineal Res; 2020 Oct; 69(3):e12683. PubMed ID: 32770854 [TBL] [Abstract][Full Text] [Related]
18. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711 [TBL] [Abstract][Full Text] [Related]
19. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far? Zhang Y; Zhong Y; Pan L; Dong J Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647 [TBL] [Abstract][Full Text] [Related]
20. Melatonin potentials against viral infections including COVID-19: Current evidence and new findings. Bahrampour Juybari K; Pourhanifeh MH; Hosseinzadeh A; Hemati K; Mehrzadi S Virus Res; 2020 Oct; 287():198108. PubMed ID: 32768490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]